Back to top

ResMed Reports Positive Results for Bilevel PAP Device Study

Read MoreHide Full Article

ResMed Inc. (RMD - Free Report) recently announced positive results from a company-sponsored research, supporting the efficiency of bilevel devices. The results were presented at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society.

Bilevel Rescue Study in Detail

ResMed compared 1,496 non-compliant patients (per U.S. Medicare guidelines), who switched to bilevel therapy. Results demonstrated that therapy compliance was achieved by around 56.8% patients when they were shifted from positive airway pressure (PAP) therapy in the first 90 days of the treatment.

Per the company, a bilevel device releases two distinct pressures, one for inhalation and the other for exhalation. Patients, who are pressure intolerant or have persistent evidence of apnea at higher pressures, are often prescribed with the advanced bilevel devices.

We believe that positive results from this study are expected to boost the uptake of the company’s bilevel devices.

A Glimpse at the Company

ResMed achieved strong global revenue growth over the past few quarters, led by sales of sleep devices, respiratory care devices, mask systems as well as software solutions. We believe, ResMed’s product launches and strategies are anticipated to gain traction in the sleep apnea market and are expected to drive growth for the company in the near term.

Among recent developments, the company informed about its first self-branded portable oxygen concentrator, Mobi, subject to launch in the fiscal third quarter. It has also introduced AirMini, the smallest PAP (positive airway pressure) device in the world.

ResMed recently received reimbursement approval for mandibular repositioning devices in France. Further, it announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term.

Moreover, the company recently announced a definitive agreement to buy HEALTHCAREfirst — a privately-held provider of software solutions and services to home health, and hospice agencies — to boost its software-as-a-service business.

Market Potential

Per a report by MarketsandMarkets, the sleep apnea devices market is expected to worth roughly $6.49 billion by 2023, at a CAGR of 7.8% between 2018 and 2023. In view of the above data, we conclude that the developmental steps undertaken by the company seem to be progressive and are strategically aligned.

Share Price Performance

In the past three months, ResMed has outperformed its industry. The stock has gained 9.2% compared with 5.2% growth recorded by the industry.

Zacks Rank & Other Key Picks

ResMed currently carries a Zacks Rank #2 (Buy).

A few other top-ranked stocks in the broader medical sector are Intuitive Surgical (ISRG - Free Report) , Illumina, Inc (ILMN - Free Report) and Amedisys, Inc. (AMED - Free Report) . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Intuitive Surgical has an expected long-term earnings growth rate of 12.1%.

Illumina expects long-term earnings growth of 20%.

Amedisys has an expected long-term earnings growth rate of 17.5%.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Intuitive Surgical, Inc. (ISRG) - free report >>

ResMed Inc. (RMD) - free report >>

Illumina, Inc. (ILMN) - free report >>

Amedisys, Inc. (AMED) - free report >>


More from Zacks Analyst Blog

You May Like